Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 15, 2015 - Issue 3
Submit an article Journal homepage
485
Views
21
CrossRef citations to date
0
Altmetric
Research Reports

Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs

Roger Rodbya Rush University, 1426 W. Washington Blvd, Chicago, IL 60607, USACorrespondence[email protected]
,
Kausik Umanathb Henry Ford Hospital, Detroit, MI, USA
,
Robert Niecestroc Independent Consultant, Pocono Pines, PA, USA
,
James H Jacksond Xcenda, Palm Harbor, FL, USA
,
Mohammed Sikae Vanderbilt University, Nashville, TN, USA
,
Julia B Lewise Vanderbilt University, Nashville, TN, USA
&
Jamie P Dwyere Vanderbilt University, Nashville, TN, USA
 show all
Pages 545-550 | Published online: 13 Dec 2014

Citations (21)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Li Li, Xin Zheng, Jin Deng, Junlin Zhou, Jihong Ou & Tao Hong. (2022) Ferric citrate for the treatment of hyperphosphatemia and anemia in patients with chronic kidney disease: a meta-analysis of randomized clinical trials. Renal Failure 44:1, pages 1113-1123.
Read now
Jolanta Malyszko & Jacek S. Malyszko. (2016) Emerging drugs for the treatment of kidney disease-induced anemia. Expert Opinion on Emerging Drugs 21:3, pages 315-330.
Read now
Amy Barton Pai, Soo Min Jang & Nicole Wegrzyn. (2016) Iron-based phosphate binders – a new element in management of hyperphosphatemia. Expert Opinion on Drug Metabolism & Toxicology 12:1, pages 115-127.
Read now

Articles from other publishers (18)

Antonio Bellasi & Geoffrey A. Block. 2023. Handbook of Dialysis Therapy. Handbook of Dialysis Therapy 372 377 .
Jonathan W. Bazeley & Jay B. Wish. (2022) Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD: A Review. American Journal of Kidney Diseases 79:6, pages 868-876.
Crossref
Kyoko Ito, Keitaro Yokoyama, Masaaki Nakayama, Masafumi Fukagawa & Hideki Hirakata. (2022) Ferric citrate hydrate is associated with a reduced cost of drugs and a smaller change in red blood cell distribution width. Scientific Reports 12:1.
Crossref
Daniel W. Coyne, Linda H. Ficociello, Vidhya Parameswaran, Melissa M. Rosen, Claudy Mullon, Robert J. Kossmann & Stuart M. Sprague. (2020) Sucroferric Oxyhydroxide in Maintenance Hemodialysis: A Retrospective, Comparative Cohort Study. Kidney Medicine 2:3, pages 307-316.
Crossref
Tomas Ganz, Avi Bino & Isidro B. Salusky. (2019) Mechanism of Action and Clinical Attributes of Auryxia® (Ferric Citrate). Drugs 79:9, pages 957-968.
Crossref
Takayuki Hamano. (2018) Mineral and bone disorders in conventional hemodialysis: Challenges and solutions. Seminars in Dialysis 31:6, pages 592-598.
Crossref
Marinella Ruospo, Suetonia C Palmer, Patrizia Natale, Jonathan C Craig, Mariacristina Vecchio, Grahame J Elder & Giovanni FM Strippoli. (2018) Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database of Systematic Reviews 2018:8.
Crossref
Takeo Ishii, Yukiko Nakajima & Kunio Oyama. (2017) Comparative analysis of the phosphate-binding effects of sucroferric oxyhydroxide, ferric citrate, and lanthanum carbonate. Renal Replacement Therapy 3:1.
Crossref
Maki Hiratsuka, Katsushi Koyama, Kinya Sengo, Jun Yamamoto, Aiko Narita, Chiharu Ito, Satoshi Kominato, Arata Hibi, Keisuke Kamiya, Rumi Miyahara, Junichi Fujikawa & Toshiyuki Miura. (2017) Long-term iron accumulation in dialysis patients treated with ferric citrate hydrate: a single-center, 80-week retrospective study in Japan. Renal Replacement Therapy 3:1.
Crossref
Wendy L. St. Peter, Lori D. Wazny, Eric Weinhandl, Katie E. Cardone & Joanna Q. Hudson. (2017) A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?. Drugs 77:11, pages 1155-1186.
Crossref
Steven M. Brunelli, Scott P. Sibbel, David Van Wyck, Amit Sharma, Andrew Hsieh & Glenn M. Chertow. (2017) Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Model. Drugs in R&D 17:1, pages 159-166.
Crossref
Takayuki Hamano, Yusuke Sakaguchi, Naohiko Fujii & Yoshitaka Isaka. (2016) Clinical features of CKD-MBD in Japan: cohort studies and registry. Clinical and Experimental Nephrology 21:S1, pages 9-20.
Crossref
Laura Kooienga, Antonio Bellasi & Geoffrey A. Block. 2017. Handbook of Dialysis Therapy. Handbook of Dialysis Therapy 698 705.e2 .
Jamie P. Dwyer. (2016) We Give Too Much Intravenous Iron. Seminars in Dialysis 29:4, pages 309-311.
Crossref
Geoffrey A. Block. (2016) Ferric Citrate in Patients With Chronic Kidney Disease. Seminars in Nephrology 36:2, pages 130-135.
Crossref
Yusuke Sakaguchi. (2016) . Nihon Toseki Igakkai Zasshi 49:12, pages 778-780.
Crossref
Roger A. Rodby, Kausik Umanath, Robert Niecestro, T. Christopher Bond, Mohammed Sika, Julia Lewis & Jamie P. Dwyer. (2015) Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data. Drugs in R&D 15:3, pages 271-279.
Crossref
Diana I Jalal, Mohammed Sika, Jamie P Dwyer, Ingrid J Chang, Barbara A Greco, Marvin Sinsakul, Simin Goral & Kausik Umanath. (2015) Ferric citrate in end-stage kidney disease as a phosphate binder and source of iron: a review of clinical trials. Clinical Investigation 5:6, pages 551-559.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.